Table 3:

New pharmacologic therapies for acute treatment of migraine, with or without aura

DrugUbrogepantRimegepant*Lasmiditan†
Mechanism of actionCGRP receptor antagonistCGRP receptor antagonist5-HT1F receptor agonist
DosingOral: 50 or 100 mg as needed (max 2 doses/24 h)Oral or sublingual: 75 mg as needed (max 1 dose/24 h)Oral; 50, 100 or 200 mg as needed (max 1 dose/24 h)
Adverse effectsNausea, dizziness and dry mouthNausea and abdominal pain and dyspepsiaDizziness, drowsiness, paresthesia, nausea, vomiting and muscle weakness

  • Note: CGRP = calcitonin gene-related peptide.

  • ↵* Rimegepant is not yet approved in Canada.

  • ↵† Lasmiditan is not expected to be coming to the Canadian market at the present time. Label warning: avoid driving within 8 hours of its use.